Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma
Open Access
- 20 May 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Glioblastoma (GBM) is among the most aggressive of brain tumors and confers a dismal prognosis despite advances in surgical technique, radiation delivery methods, chemotherapy, and tumor-treating fields. While immunotherapy (IT) has improved the care of several adult cancers with previously dismal prognoses, monotherapy with IT in GBM has shown minimal response in first recurrence. Recent discoveries in lymphatics and evaluation of blood brain barrier offer insight to improve the use of ITs and determine the best combinations of therapies, including radiation. We highlight important features of the tumor immune microenvironment in GBM and potential for combining radiation and immunotherapy to improve prognosis in this devastating disease.Keywords
This publication has 136 references indexed in Scilit:
- Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapyNeuro-Oncology, 2012
- Radiation Enhances Regulatory T Cell RepresentationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in miceJournal of Clinical Investigation, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Systemic Inhibition of Transforming Growth Factor-β in Glioma-Bearing Mice Improves the Therapeutic Efficacy of Glioma-Associated Antigen Peptide VaccinesClinical Cancer Research, 2009
- STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunityNature, 2009
- The RIG-I-like Receptor LGP2 Recognizes the Termini of Double-stranded RNAJournal of Biological Chemistry, 2009
- STING is an endoplasmic reticulum adaptor that facilitates innate immune signallingNature, 2008
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme1Neuro-Oncology, 2006